The European Union’s executive branch on Monday authorized Novavax’s COVID-19 vaccine, enabling its use in all 27 member-states. The European Commission previously cleared four COVID-19 vaccines, but Novavax’s, known as Nuvaxovid, is the first protein-based one. A European Medicines Agency panel earlier Monday said data from two clinical studies showed the vaccine is efficacious, safe, and of a strong quality. The jab “together with the already authorized vaccines, will support vaccination campaigns in EU Member States during a crucial phase of the pandemic,” the commission said in a statement. Possible side effects include headaches, fever, and enlarged lymph nodes. People who have a hypersensitivity to any of the vaccine’s ingredients are being advised not to get it. The studies, one conducted in the United States and Mexico and the other performed in the United Kingdom, indicated Novavax’s shot is about 90 percent effective at preventing symptomatic COVID-19. However, both studies finished when …